Table 2: Bowel function scores, symptom scores, and IBS quality of life scores after administration of study agents (8 weeks, intention-to-treat analysis).

VariablesGJS+DUO
( )
GJS+DUO-P
( )
GJS-P+DUO
( )
GJS-P+DUO-P
( )
value

Bowel function score
 Frequency14.31 (7.38)14.00 (8.93)12.25 (7.30)12.00 (4.97)0.806
 Consistency1.19 (0.93)0.96 (0.65)1.15 (1.06)0.85 (0.69)0.862
 Ease of passage1.21 (0.73)0.80 (0.61)1.32 (1.04)0.82 (0.73)0.108
Symptom score (mm)
 Abdominal pain28.33 (20.60)27.97 (18.35)28.45 (18.55)24.61 (14.87)0.947
 Abdominal discomfort31.71 (19.44)29.93 (17.51)29.43 (19.78)27.39 (14.26)0.945
 Bloating26.08 (16.11)25.65 (15.10)31.81 (18.40)28.73 (13.83)0.752
 Flatulence25.67 (16.70)23.88 (16.07)28.27 (18.56)31.60 (16.66)0.689
 Urgency27.31 (21.53)26.00 (19.83)25.20 (15.23)27.13 (15.58)0.992
 Mucus in stool25.60 (23.75)21.81 (19.66)23.06 (16.70)28.18 (19.21)0.856
 Overall symptom32.37 (21.88)30.98 (17.43)31.55 (17.98)33.65 (14.63)0.985
IBS quality of life
 Dysphoria8.92 (7.69)9.29 (7.69)10.08 (6.29)10.42 (6.57)0.948
 Interference with activity 8.85 (7.45)7.00 (4.61)8.38 (5.01)7.92 (6.56)0.871
 Body image3.92 (3.59)2.57 (3.39)4.00 (2.90)2.92 (2.57)0.586
 Health worry3.62 (2.43)3.29 (2.09)3.85 (1.91)4.00 (2.26)0.848
 Food avoidance5.46 (2.50)5.50 (3.20)5.25 (2.49)4.17 (3.43)0.641
 Social reaction4.38 (4.75)3.50 (3.35)4.09 (3.08)3.92 (3.34)0.938
 Sexual1.46 (1.94)1.43 (1.95)1.58 (2.07)1.67 (1.61)0.988
 Relationship2.62 (2.79)2.29 (1.73)3.15 (2.30)2.42 (2.31)0.781
 Overall39.23 (30.43)34.86 (24.14)39.85 (22.97)37.42 (24.43)0.958

GJS: Gwakhyangjeonggisan, DUO: Duolac7S, GJS-P: placebo of Gwakhyangjeonggisan, DUO-P: placebo of Duolac7S.
All values were analyzed by Fisher’s exact test for categorical variables and one-way ANOVA for continuous variables.
All scores are presented as mean (standard deviation).
Used a scale of 1–7: 1, watery stool; 7, hard, lumpy stool (based on Bristol stool form scale).
Used a scale of 1–7: 1, fecal incontinence; 7, manual disimpaction.